Aldeyra Therapeutics (ALDX) Citi's 2024 Global Healthcare Conference summary

Pipeline and product overviews

• LENZ developed a daily eye drop for presbyopia, targeting a $128 million TAM, with a PDUFA date in August and strong phase III results showing rapid and lasting vision improvement.

• Aldeyra's lead product, reproxalap, targets dry eye disease and allergic conjunctivitis, with rapid onset of action and a robust pipeline including retina and systemic programs.

• Opthea is advancing a first-in-class VEGF-C/D trap for wet AMD, aiming to improve vision outcomes by combining with existing anti-VEGF-A therapies, with phase III readouts expected next year.

Value propositions and differentiation

• LENZ's eye drop offers a convenient alternative to reading glasses, with rapid and durable efficacy, outperforming previous products like Vuity in both speed and magnitude of effect.

• Aldeyra's reproxalap provides fast relief for dry eye and allergic conjunctivitis, addressing a significant overlap in patient populations and offering a unique one-stop solution.

• Opthea's combination approach addresses unmet needs in wet AMD, showing superior visual and anatomical outcomes in phase IIb, and aims to supplement rather than compete with current therapies.

Commercialization strategies

• LENZ plans a three-pillar strategy: physician engagement via a 100-person sales force, direct-to-consumer (DTC) branding, and seamless patient access, targeting early adopters like LASIK patients and contact lens users.

• Aldeyra leverages a partnership with AbbVie for commercialization, with a co-promotion model and focus on broad optometry reach.

• Opthea employs a business-to-business model, targeting four major retina networks that control 70% of U.S. injection volume, requiring a small commercial team.